TOP STORIES
Mylan has rejected Teva’s unsolicited bid.
Robert J. Coury, Mylan’s executive chairman, said Teva’s roughly $40 billion offer grossly undervalues the company and “would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares.” He added that the transaction “lacks industrial logic and carries significant global antitrust risk.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Intarcia Therapeutics raised $225 million to develop its implantable drug-delivery pump for patients with diabetes.
Medtronic has agreed to halt production and distribution of its SynchroMed implantable drug pump used to deliver pain meds to cancer patients after U.S. regulators said it failed to fix the device, which can deliver too much or too little medication.
LIFE SCIENCE
More Mylan news: The company has recalled 8 lots of injected cancer medication, mostly made for Pfizer, after particulates were found in some vials.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
aTyr Pharma’s Resolaris facioscapulohumeral muscular dystrophy treatment has received Orphan Drug Designation.
The FDA has fast-tracked Sanofi’s Fabry treatment.
No surprise. Still sad. Layoffs coming at Celladon.
Merck’s Januvia diabetes treatment moves past a basic heart safety trial
Researchers have discovered how an abundant class of RNA genes, called lncRNAs can regulate key genes.
By studying an important lncRNA, called Xist, the scientists identified how this RNA gathers a group of proteins and ultimately prevents women from having an extra functional X-chromosome — a condition in female embryos that leads to death in early development. These findings mark the first time that researchers have uncovered the mechanism of action for lncRNA genes.
John Oliver takes his turn to rip apart Dr. Oz. Apparently the daytime TV show host is still getting burned.
PAYERS-PROVIDERS
The investor of Now Health International has acquired Best Doctors Insurance.
This looks bad: health insurance companies could take about 18 percent of a $1 billion settlement for professional football players with brain injury.
The Medical Center of Central Georgia in Macon has agreed to pay the federal government $20 million to settle over-billing allegations.
TECH
Great question: When has analytics ever said – “You’re awesome”?
InteraXon, which makes the smartphone-connected brainwave sensing device Muse, has raised $11 million.
MIT published a new report that indicates the U.S. might not be the leader in R&D anymore.
Mount Sinai adopted health IT startup par80 referral service.
POLITICS
A group of House Democrats are pushing to repeal Obamacare’s “Cadillac tax,” which they say unfairly targets people in more expensive areas.
Healthcare customers who receive benefits above $10,200 for individual coverage and $27,500 for family coverage will be forced to pay a tax of 40 percent. Republicans, as well as some Democrats, have blasted the tax because it is tied to general cost of living measures, rather than growth in healthcare costs.
A LITTLE EXTRA
Google announced the launch of a new marketplace that will allow the company purchase patents from those wanting to sell.
The company says its new “Patent Purchase Promotion,” opening next month, is an effort to “remove friction” from a patent market that is fraught with patent trolls, lawsuits and other wasted efforts.
The Morning Read provides a 24-hour wrap up of everything else healthcare’s innovators need to know about the business of medicine (and beyond). The author of The Read published it but all full-time MedCity News journalists contribute to its content.
